Navigation Links
Savient Pharmaceuticals Announces New Data Surrounding KRYSTEXXA® and the Impact of Refractory Chronic Gout at the American College of Rheumatology Meeting
Date:11/5/2011

ysician office visits, laboratory services, and ancillary services than patients in the control group without tophi or gout flares (p<0.001). A comparison of patient records revealed that total 12-month costs averaged $21,059 among patients with tophi and greater than or equal to 3 gout flares compared to $10,657 for patients in the control group (p<0.001). In addition, patients with tophi and greater than or equal to 6 gout flares had even higher resource utilization and overall healthcare costs totaling $32,178 compared to the control group (p<0.01).

"The gout epidemiology data presented at the ACR meeting underscore the importance of initiating early treatment with the appropriate medication to minimize the mental, physical and economic impact of gout and refractory chronic gout," commented Herbert S. B. Baraf, M.D., Clinical Professor of Medicine at The George Washington University School of Medicine and an investigator who conducted clinical trials with KRYSTEXXA. "Recently published data demonstrated that treatment with KRYSTEXXA resulted in significant and sustained reductions in uric acid levels and clinical improvements in RCG patients. The data from the post-hoc analysis of the KRYSTEXXA pivotal and extension studies will add to physicians' knowledge of the treatment and provide them with a straightforward approach for managing the risk of potential infusion reactions."

ABOUT THE STUDIESComplete abstracts can be found online via the following links:

Characterization and Management of Infusion Reactions in Refractory Chronic Gout (RCG) Treated with Pegloticase (KRYSTEXXA)
Presentation Number: 2582
Wednesday, November 9, 2011: 9:45 AM
Oral presentation W 474 A (McCormick Place Convention Center)

Patient Management/Treatment and Outcomes of Gout Between Primary Care P
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Savient Pharmaceuticals Reports Third Quarter 2011 Financial Results
2. Savient Pharmaceuticals to Hold Third Quarter 2011 Financial Results Conference Call on Thursday, November 3, 2011
3. Savient Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference
4. Savient Pharmaceuticals Names Kenneth J. Zuerblis Chief Financial Officer
5. Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients
6. Savient Pharmaceuticals to Present at the Wedbush Securities 2011 Life Sciences Management Access Conference
7. Savient Pharmaceuticals Reports Second Quarter 2011 Financial Results
8. Savient Pharmaceuticals to Hold Second Quarter 2011 Financial Results Conference Call on Thursday, August 4, 2011
9. Savient Pharmaceuticals Marketing Authorization Application for KRYSTEXXA® Accepted for Review by European Medicines Agency
10. Savient Pharmaceuticals Reports First Quarter 2011 Financial Results
11. Savient Pharmaceuticals Submits European Marketing Authorization Application for KRYSTEXXA®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... , May 22, 2015  Research and Benchmarking ... sixth Medical Affairs Roundtable on Thursday, ... a virtual roundtable to discuss "Medical Affairs, Role ... Best Practices, Medical Affairs Consortium provides Medical Affairs ... the key challenges they face. The consortium has ...
(Date:5/22/2015)... May 22 2015 /CNW/ - The Taskforce representing ... of all the hard work that the Minister and Health ... months. This program recognizes the needs of the thalidomide survivors, ... $75,000 a year, tax free, with annual adjustments for inflation. ... for annual payments of $100,000 based on the severity of ...
(Date:5/22/2015)... , May 22, 2015  Amgen (NASDAQ: ... has commenced termination of its participation in ... AstraZeneca (LON:AZN, STO:AZN and NYSE: AZN ... in development for patients with moderate-to-severe plaque ... decision was based on events of suicidal ...
Breaking Medicine Technology:Best Practices Sixth Medical Affairs Consortium Roundtable to Focus on Health Economics & Outcomes Research 2Amgen to terminate participation in co-development and commercialization of brodalumab 2Amgen to terminate participation in co-development and commercialization of brodalumab 3Amgen to terminate participation in co-development and commercialization of brodalumab 4Amgen to terminate participation in co-development and commercialization of brodalumab 5
... BLUE BELL, Pa., Feb. 2, 2011 Inovio Pharmaceuticals, ... in the development of therapeutic and preventive vaccines against ... a scientific paper in the journal Human Vaccines ... of Inovio,s SynCon™ DNA vaccine for prostate cancer targeting ...
... LIONVILLE, Pa., Feb. 1, 2011 West Pharmaceutical Services, Inc. ... attend the UBS 21st Annual Global Healthcare Services Conference in ... business and outlook on Tuesday, February 8, 2011 at 1:00 ... Company,s presentation, as well as a copy of the presentation ...
Cached Medicine Technology:Inovio Pharmaceuticals' Dual-Antigen SynCon™ DNA Vaccine for Prostate Cancer Induces Robust Responses in Preclinical Trial 2Inovio Pharmaceuticals' Dual-Antigen SynCon™ DNA Vaccine for Prostate Cancer Induces Robust Responses in Preclinical Trial 3Inovio Pharmaceuticals' Dual-Antigen SynCon™ DNA Vaccine for Prostate Cancer Induces Robust Responses in Preclinical Trial 4Inovio Pharmaceuticals' Dual-Antigen SynCon™ DNA Vaccine for Prostate Cancer Induces Robust Responses in Preclinical Trial 5
(Date:5/23/2015)... 2015 Add High-Quality prismatic refractions into footage ... , It's as simple as dragging and dropping footage into ... for full effect. , Including over 80 stunning flares, ... sensors making this the ultimate bundle for adding prismatic refractions ... this package are movie files designed for Final Cut Pro ...
(Date:5/22/2015)... Utah (PRWEB) May 22, 2015 Mountain Point ... host a ribbon cutting ceremony on Friday, May 29, 2015 ... p.m. to 6 p.m. The new medical center, set to ... North Triumph Boulevard, Lehi, UT 84043. , “The opening ... our team and the Utah County community,” said Kent Loosle, ...
(Date:5/22/2015)... (PRWEB) May 22, 2015 Combination ... treatment option for chronic obstructive pulmonary disorder (COPD) ... plc and AstraZeneca plc as well as Germany’s ... share and position. But will market payers, clinicians ... already well-entrenched products to completely new ones? , ...
(Date:5/22/2015)... 2015 Coordinating care for people ... Historically providers have not been reimbursed or rewarded ... 2015, Medicare has paved the way by offering ... the launch of Oculus Health , an ... using the platform will now be able to ...
(Date:5/22/2015)... 22, 2015 ZH Healthcare ... solutions, announced today that Bill Lane, joins ZH’s ... developer of BlueEHS,a first of its kind, Freemium ... customizable Electronic Health Records (EHR) with an integrated ... telemedicine-enabled comprehensive patient portal, and more. Combined with ...
Breaking Medicine News(10 mins):Health News:Developers at Pixel Film Studios Release ProFlare 5K Prism for Final Cut Pro X. 2Health News:Mountain Point Medical Center, a Campus of Jordan Valley Medical Center, Hosts Ribbon Cutting Ceremony and Community Celebration on Friday, May 29, 2015 2Health News:Chronic Obstructive Pulmonary Disorder Therapeutics Market Discussed in In-demand FirstWord Report Published at MarketPublishers.com 2Health News:Oculus Health Care Coordination Platform Officially Launched 2Health News:Oculus Health Care Coordination Platform Officially Launched 3Health News:Oculus Health Care Coordination Platform Officially Launched 4Health News:ZH Healthcare Adds Bill Lane to Advisory Board 2
... NRL: THE NEW STANDARDIZED SOURCE MATERIAL FOR THE PRODUCTION ... PRODUCTS USING ... Technology Limited has invited,Vystar Corporation to present its revolutionary ... Conference 2008 in Madrid in,January. "Vytex(TM) Natural Rubber ...
... Spain: In a surprising finding, American scientists have found ... as well as their single counterparts in certain aspects ... study, presented today (Wednesday) at the European Cancer Conference ... 489 patients with Barretts oesophagus, a non-cancerous condition linked ...
... that attacks cancer in an entirely new way has ... the disease and prolonging the lives of patients. , ... Conference (ECCO 14) in Barcelona found that giving the ... the amount of time patients survived without progression of ...
... and Vicksburg Plants Recognized as Premier,Facilities by the Association for ... ... Magazine, BATESVILLE, Ind., Sept. ... Hillenbrand Industries (HB),announced that its two metal manufacturing facilities and ...
... Proposals and Variations, LOS ANGELES, Sept. ... a leading e-health Wi-Fi PDA technology provider, ... and EMR applications,and the distributor of life ... products, announced today that its Board of ...
... newly incorporated subsidiary of Genomatix Software GmbH, has announced that ... the NCI/NIH for the fourth consecutive year. This years renewal ... was executed entirely between the US company and the NCI/NIH ... with our progress in putting the US company on its ...
Cached Medicine News:Health News:Global Latex Conference to Showcase Vytex(TM) NRL 2Health News:Married esophageal cancer patients fare worse in some quality of life aspects than single patients 2Health News:New type of drug shows promise in attacking melanoma in an innovative way 2Health News:Three Batesville Casket Company Production Facilities Honored for Manufacturing Expertise by National Organizations 2Health News:Three Batesville Casket Company Production Facilities Honored for Manufacturing Expertise by National Organizations 3Health News:InstaCare Corp. Reviewing M&A Plans 2
... drainage from the ureteropelvic junction to the ... segment with no sideports prevents postoperative narrowing ... of the ureteral wall to the stent. ... one-time use. CAUTION: Periodic evaluation is advised; ...
Used for retrograde positioning of a ureteral stent. The radiopaque band improves fluoroscopic visibility of the positioner tip. Supplied sterile in peel-open packages. Intended for one-time use....
... silicone or Silitek, ACMI Single J ... healing after surgery. Following cystectomy, the ... supports the ileal intestinal anastomosis, and ... leakage. Following ureteroscopy, the Single J ...
... The V-Max™ Roller Bar Electrode provides ... and improve visibility during TURP procedures. The ... surface with holes. The holes have circular ... tissue ablation. This patented design was developed ...
Medicine Products: